OIG Still Wary Of Anti-Kickback Safe Harbors For Value-Based Arrangements Involving Drugs
US health department’s Office of Inspector General reviews its concerns with allowing remuneration from drug firms in value-based arrangements in latest report to Congress.
You may also be interested in...
Score of slimmed down Medicare negotiations in the Build Back Better legislation is $79bn, a far cry from the $456bn in savings projected from the draconian HR 3. But the bill’s overall impact on the deficit means that pharma might get a total reprieve – or go back on the chopping block.
Sample program focuses only on inpatient use and in hospitals that do not accept Prescription Drug Marketing Act-compliant trial units. By improving adherence, program could lower federal health care costs over time, Office of Inspector General suggests.
In rare loss for FDA, appeals court reverses district court decision tossing Catalyst’s suit over Orphan Drug Act, saying deference should not have been granted to agency’s interpretation. District court finds it is too early to rule on one Pfizer charity co-pay program but backs broad reading of Anti-Kickback Statute.